Table 3. Association between clinicopathological factors and the response of primary tumors (univariate analysis).
| Clinicopathological factors† | No. of patients (%) | Response of primary tumors | χ2/Z | P value | |
|---|---|---|---|---|---|
| No pCR, n (%) | pCR, n (%) | ||||
| Menstrual status‡ | 2.6966 | 0.2597 | |||
| Premenopausal | 445 (34.3) | 391 (87.9) | 54 (12.1) | ||
| Perimenopausal | 513 (39.5) | 446 (86.9) | 67 (13.1) | ||
| Postmenopausal | 340 (26.2) | 308 (90.6) | 32 (9.4) | ||
| Lesion side‡ | 0.8514 | 0.3562 | |||
| Left | 688 (53.2) | 612 (89.0) | 76 (11.0) | ||
| Right | 606 (46.8) | 529 (87.3) | 77 (12.7) | ||
| cT§ | ‒4.1050 | <0.0001*** | |||
| T1 | 129 (10.0) | 99 (76.7) | 30 (23.3) | ||
| T2 | 918 (71.0) | 813 (88.6) | 105 (11.4) | ||
| T3 | 246 (19.0) | 228 (92.7) | 18 (7.3) | ||
| cN§ | ‒7.3860 | <0.0001*** | |||
| N0 | 489 (37.7) | 386 (78.9) | 103 (21.1) | ||
| N1 | 593 (45.7) | 555 (93.6) | 38 (6.4) | ||
| N2 | 166 (12.8) | 160 (96.4) | 6 (3.6) | ||
| N3 | 50 (3.8) | 44 (88.0) | 6 (12.0) | ||
| Histology (biopsy)‡ | 0.3984 | 0.5279 | |||
| Invasive ductal | 1,269 (98.8) | 1,117 (88.0) | 152 (12.0) | ||
| Invasive lobular | 15 (1.2) | 14 (93.3) | 1 (6.7) | ||
| Histological Grade (biopsy)‡ | 315.3609 | <0.0001*** | |||
| I | 34 (2.6) | 32 (94.1) | 2 (5.9) | ||
| II | 725 (55.9) | 715 (98.6) | 10 (1.4) | ||
| III | 162 (12.5) | 159 (98.1) | 3 (1.9) | ||
| Unknown | 377 (29.0) | 239 (63.4) | 138 (36.6) | ||
| ER status (biopsy)‡ | 28.6713 | <0.0001*** | |||
| Negative | 505 (39.0) | 415 (82.2) | 90 (17.8) | ||
| Positive | 790 (61.0) | 727 (92.0) | 63 (8.0) | ||
| PR status (biopsy)‡ | 41.8765 | <0.0001*** | |||
| Negative | 697 (53.9) | 577 (82.8) | 120 (17.2) | ||
| Positive | 595 (46.1) | 562 (94.5) | 33 (5.5) | ||
| HER2 (biopsy)‡ | 7.7216 | 0.0211* | |||
| Negative | 652 (50.2) | 589 (90.3) | 63 (9.7) | ||
| Positive | 441 (34.0) | 385 (87.3) | 56 (12.7) | ||
| Unknown | 205 (15.8) | 171 (83.4) | 34 (16.6) | ||
| Ki67 expression (biopsy)‡ | 19.0551 | <0.0001*** | |||
| Low | 350 (27.2) | 331 (94.6) | 19 (5.4) | ||
| High | 939 (72.8) | 805 (85.7) | 134 (14.3) | ||
| Course of CT (cycles)‡ | 0.1921 | 0.6612 | |||
| <5 | 1,200 (92.6) | 1,057 (88.1) | 143 (11.9) | ||
| ≥5 | 96 (7.4) | 86 (89.6) | 10 (10.4) | ||
| Regimen‡ | 0.2175 | 0.6409 | |||
| CT only | 1,273 (98.2) | 1,122 (88.1) | 151 (11.9) | ||
| CT + Anti-HER2 | 23 (1.8) | 21 (91.3) | 2 (8.7) | ||
†, Those clinicopathological factors with fewer than 10 patients were excluded in this analysis; ‡, Chi-squared test was used; §, Wilcoxon rank-sum test was used; *, P<0.05; ***, P<0.001. pCR, pathologic complete response; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CT, chemotherapy.